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SCIENTIFIC OPINION 
Scientific Opinion on the Tolerable Upper Intake Level of vitamin D
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was 
asked to re-evaluate the safety in use of vitamin D and to provide, if necessary, revised Tolerable Upper Intake 
Levels (ULs) of vitamin D for all relevant population groups. The ULs for adults including pregnant and 
lactating women, children and adolescents were revised. For adults, hypercalcaemia was selected as the indicator 
of toxicity. In two studies in men, intakes between 234 and 275 µg/day were not associated with hypercalcaemia, 
and a no observed adverse effect level (NOAEL) of 250 µg/day was established. Taking into account 
uncertainties associated with these studies, the UL for adults including pregnant and lactating women was set at 
100 µg/day. Despite a continuing paucity of data for high vitamin D intakes in children and adolescents, the UL 
was adapted to 100 µg/day for ages 11-17 years, considering that owing to phases of rapid bone formation and 
growth this age group is unlikely to have a lower tolerance for vitamin D compared to adults. The same applies 
also to children aged 1-10 years, but taking into account their smaller body size, a UL of 50 µg/day is proposed. 
For infants, the UL of 25 µg/day based on previously available data relating high vitamin D intakes to impaired 
growth and hypercalcaemia was retained as limited additional evidence has emerged since the previous risk 
assessment. Data on vitamin D intakes from surveys in 14 European countries indicate that intakes in high 
consumers are below the revised ULs for vitamin D for all population groups. © European Food Safety 
Authority, 2012 
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to re-evaluate the safety in use of vitamin D and to provide, if necessary, revised 
Tolerable Upper Intake Levels (ULs) of vitamin D for all relevant population groups. 
Vitamin D derives from the diet but can also be synthesised in the skin under the influence of UV-B 
radiation. Serum 25(OH)D concentration is a good marker of vitamin D status, but can only be used 
as a biomarker of vitamin D intake in people with low exposure to sunlight. Following ingestion of 
large doses of vitamin D, the concentration of 25(OH)D in serum increases, while that of the active 
metabolite 1,25(OH)2D is unchanged or even reduced. Very high serum 25(OH)D concentrations 
may lead to hypercalcaemia, which is considered the critical effect of excess intake of vitamin D. 
Hypercalciuria can be associated with hypercalcaemia, but it can also occur without. 
For the derivation of the UL, the occurrence of hypercalcaemia and hypercalciuria has been assessed 
in studies using daily or weekly supplementation of vitamin D for several weeks to months. The 
shorter-term studies were generally performed in seasons of low sun exposure. Study populations 
were not generally vitamin D-deficient, and two studies were conducted in subjects with a high 
vitamin D status at baseline. Study populations included whites, African Americans, young men, pre- 
and postmenopausal women, elderly nursing home residents, and overweight and obese adults. It was 
concluded that vitamin D at doses up to 275 µg/day does not lead to persisting hypercalcaemia or 
hypercalciuria in adults.  
Long-term health outcomes (all-cause mortality, cardiovascular disease, cancer, fractures and kidney 
stones) were also considered, but no studies reported an association between vitamin D intake and 
increased risk for adverse long-term health outcomes. Studies reporting on an association between 
25(OH)D concentration and all-cause mortality or cancer were inconsistent. When 25(OH)D 
concentrations were associated with an increased risk for adverse long-term health outcomes in some 
studies, there was a wide variation in 25(OH)D concentrations associated with the adverse effect. It 
was considered that 25(OH)D concentrations cannot be used to characterise the risk for adverse 
long-term health outcomes.  
In adults, a daily vitamin D dose of 250 µg/day (range 234-275 µg/day) was considered to reflect a 
no observed adverse effect level (NOAEL). This value was based on only two studies of short 
duration (up to five months) in small samples of healthy young men with minimal sun exposure. To 
take into account the uncertainties associated with this value, an uncertainty factor of 2.5 was chosen, 
and the UL was established at 100 µg/day. It was considered that the UL of 100 µg/day for adults 
also applies to pregnant and lactating women. This UL is supported by two studies in pregnant and 
lactating women, both using doses of vitamin D2 or D3 up to 100 µg/day for several weeks to months, 
which did not report adverse events for either the mothers or their offspring. 
For infants, there is historical evidence on retarded growth from a study in which infants received 
various regimens of vitamin D exceeding 45 µg/day up to one year of age, although another small 
study using doses up to 54 µg vitamin D/day until about five months of age did not show such an 
effect. More recent intervention studies using doses up to 25 µg vitamin D/day (plus the amount 
ingested via fortified infant formula) for up to five months after birth did not indicate that these 
intakes are associated with hypercalcaemia in infants. As new data from intervention studies in 
healthy infants have not become available since the previous risk assessment by the SCF (2003), it 
was decided that the UL of 25 µg vitamin D/day previously derived for infants from 0 to 12 months 
of age should be retained. 
For children and adolescents aged 10-17 years, there is limited evidence from two studies showing 
that vitamin D intakes at doses up to 50 µg/day do not lead to hypercalcaemia. While there are no 
Tolerable Upper Intake Level of vitamin D 
 
EFSA Journal 2012;10(7):2813 3 
studies at higher intakes, it was considered that there is no reason to believe that adolescents in the 
phase of rapid bone formation and growth have a lower tolerance for vitamin D compared to adults, 
and a UL of 100 µg/day for adolescents aged 11-17 years was proposed. 
For children aged 1-10 years, no new data from intervention studies have emerged since the previous 
risk assessment. It was considered that there is no reason to believe that children aged 1-10 years in 
the phase of rapid bone formation and growth have a lower tolerance for vitamin D compared to 
adults, and, by taking into account their smaller body size, a UL for vitamin D of 50 µg/day was 
proposed. 
Data from European populations indicate that vitamin D intakes from all sources in high consumers 
are below the UL for all population subgroups (i.e., about 25 %, 75 %, 30 % and 8 % of the UL for 
adults, infants, children and adolescents, respectively).  
 
Tolerable Upper Intake Level of vitamin D 
 
EFSA Journal 2012;10(7):2813 4 
TABLE OF CONTENTS 
Abstract .................................................................................................................................................... 1 
Summary .................................................................................................................................................. 2 
Table of contents ...................................................................................................................................... 4 
Background as provided by the European Commission .......................................................................... 5 
Terms of reference as provided by the European Commission ............................................................... 5 
Assessment ............................................................................................................................................... 6 
1. Introduction ..................................................................................................................................... 6 
2. Dietary intakes ................................................................................................................................. 7 
2.1. Adults ...................................................................................................................................... 7 
2.2. Infants (≤1 year) ...................................................................................................................... 7 
2.3. Children (approximately 1-14 years) ...................................................................................... 8 
2.4. Adolescents ............................................................................................................................. 8 
3. Hazard identification ....................................................................................................................... 8 
3.1. Vitamin D physiology ............................................................................................................. 8 
3.2. Biomarkers of vitamin D intake .............................................................................................. 9 
3.3. Biomarkers of vitamin D status and activity .......................................................................... 9 
3.4. Mechanisms of toxicity ......................................................................................................... 10 
3.5. Adverse effects of excess vitamin D intake .......................................................................... 10 
3.5.1. Vitamin D intake and hypercalcaemia in adults ............................................................... 10 
3.5.2. Serum 25(OH)D concentration and hypercalcaemia in adults ......................................... 12 
3.5.3. Vitamin D intake or status and long-term health outcomes in adults .............................. 12 
3.5.4. Adverse effects of vitamin D intake in pregnant and lactating women ........................... 14 
3.5.5. Adverse effects of vitamin D intake in infants ................................................................. 15 
3.5.6. Vitamin D intake and hypercalcaemia in children and adolescents ................................. 16 
4. Dose-response assessment and derivation of a Tolerable Upper Intake Level ............................. 17 
4.1. Adults .................................................................................................................................... 17 
4.2. Pregnant and lactating women .............................................................................................. 17 
4.3. Infants ................................................................................................................................... 17 
4.4. Children and adolescents ...................................................................................................... 18 
4.5. Summary of Tolerable Upper Intake Levels for vitamin D .................................................. 18 
5. Characterisation of the risk............................................................................................................ 18 
Conclusions ............................................................................................................................................ 18 
References .............................................................................................................................................. 18 
Appendices ............................................................................................................................................. 27 
A. Intake of vitamin D among adults in European countries ............................................................. 27 
B. Intake of vitamin D among children in European countries .......................................................... 33 
C. Vitamin D intake and hypercalcaemia in adults ............................................................................ 37 
Glossary and Abbreviations ................................................................................................................... 45 
Tolerable Upper Intake Level of vitamin D 
 
EFSA Journal 2012;10(7):2813 5 
BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
Vitamin D has been assessed in the past by the Scientific Committee on Food. In the Opinion on the 
Tolerable Upper Intake Level (UL) of vitamin D of 4 December 2002 the Committee set the following 
UL values for vitamin D: 
 50 g vitamin D/day for adults; 
 25 g vitamin D/day for infants 0-2 years of age; 
 25 g vitamin D/day for children from 3-10 years of age; 
 50 g vitamin D/day for adolescents 11-17 years of age. 
On 30 November 2010, the American Institute of Medicine (IoM) published a report on “Dietary 
Reference Intakes for Calcium and Vitamin D” (IoM, 2010). In this report, the IoM proposes new 
reference values and UL values for vitamin D which, as stated in the report “are based on much more 
information and higher-quality study results than were previously available”.  
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
In accordance with Article 29 (1) (a) of Regulation (EC) No 178/2002, the European Commission 
asks the European Food Safety Authority to: 
- re-evaluate the safety in use of vitamin D,  
- if necessary, provide revised tolerable upper intake levels, that are unlikely to pose a risk of 
adverse health effects, for vitamin D for all relevant population groups. 
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ASSESSMENT 
1. Introduction 
The principal physiological function of vitamin D in all vertebrates including humans is to maintain 
serum calcium and phosphorus concentrations in a range which supports cellular processes, 
neuromuscular function, and bone ossification.  
It has become increasingly apparent that vitamin D also has other important functions in tissues not 
primarily related to mineral metabolism (Bouillon et al., 2008; Holick, 2006). Examples are its role in 
modulating the renal production of renin and its role in insulin secretion. The active metabolite, 
1,25(OH)2D, regulates the transcription of a large number of genes through binding to a transcription 
factor, the vitamin D receptor.  
In 2003, the Scientific Committee on Food (SCF, 2003) established a Tolerable Upper Intake Level 
(UL) of vitamin D for adults, including pregnant and lactating women, of 50 µg/day. This UL was 
based on the increased risk of hypercalcaemia observed after intakes of around 100 µg vitamin D/day 
in the highest dose group in one (Narang et al., 1984) of three studies. An uncertainty factor of 2 was 
applied to account for inter-individual variation. For infants and young children aged 0-24 months the 
UL was set at 25 µg/day based on the absence of hypercalcaemia attributable to intervention with 
vitamin D in two studies in which breast-fed or formula-fed infants received 25 µg vitamin D/day 
(plus the amount ingested via fortified infant formula) for some months. The UL for children aged 
3-10 years was set at 25 µg/day and for adolescents aged 11-17 years at 50 µg/day, though data on 
supplementation with vitamin D doses ≥20 µg/day were lacking.  
The UL for vitamin D for adults established by the SCF (2003) was 50 µg/day, the same as that from 
the US Institute of Medicine (IoM, 1997). It was derived from a no observed adverse effect level 
(NOAEL) of 60 µg/day, by applying an uncertainty factor of 1.2 to account for the small sample size 
and short duration of the single study (Narang et al., 1984) on which the NOAEL was based. The 
same UL of 50 µg/day was set for pregnant and lactating women and for children beyond one year of 
age. For infants, a UL of 25 µg/day was set based on normal growth in formula-fed infants ingesting 
34.5-54.3 µg vitamin D/day, by applying an uncertainty factor of 1.8 to the mean of the lower and 
upper dose range (44.4 µg) to account for the insensitivity of the end point and the small sample size 
of the study. 
In 2011, the IoM published its re-assessment of the UL for vitamin D and considered an intake of 
250 µg vitamin D/day as a NOAEL, but also used information on 25(OH)D concentrations achieved 
during considerable sun exposure as well as evidence from observational studies on chronic disease 
outcomes suggesting an increase in risk associated with 25(OH)D concentrations above 
approximately 125 to 150 nmol/L. Based on one dose-response study, vitamin D intakes of 
125 µg/day were judged as not increasing 25(OH)D concentration beyond 150 nmol/L. An 
uncertainty factor of 1.2 was applied to take into account various uncertainties and the reliance on a 
single study. The UL for adults, including pregnant and lactating women, was set at 100 µg/day. The 
same UL was set for children and adolescents aged 9-18 years, while the value was scaled down for 
young children and those aged 4-8 years. For infants aged 0-6 months, a UL of 25 µg/day was set 
based on normal growth in infants receiving a mean of 44.4 µg vitamin D/day, applying an 
uncertainty factor of 2 to ensure absence of toxicity also in small infants, and then rounding. In infants 
aged 6-12 months with a greater body size, the UL was set at 38 µg/day (IoM, 2010).  
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This opinion relates to the evaluation of the safety in use of vitamin D forms authorised for addition 
to foods
4
 or food supplements
5
, i.e. cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2). The 
two forms only differ by their side chains on the sterol skeleton (Holick, 2006). The term vitamin D 
without a subscript relates to either or both vitamin D2 or vitamin D3 and its metabolites. Only data on 
oral intake of vitamin D will be considered for this opinion. 
2. Dietary intakes 
Few foods naturally contain vitamin D. Some higher fungi such as mushrooms are a natural source of 
vitamin D2. Animal foods such as fatty fish, liver, fish liver oils and egg yolks contain vitamin D3. 
Further sources of vitamin D are fortified foods (most often milk, margarine and/or butter, and 
breakfast cereals) and dietary supplements.  
Mean intakes of vitamin D in European countries vary according to sex, age, and supplementation 
habits (Appendices A and B). There is a large diversity in the methodology used to assess the 
individual intakes of children, adolescents and adults. These differences in dietary assessment 
methods make direct comparisons difficult. Data from Poland based on a single 24-h recall have been 
listed in Appendices A and B for completeness but have not been considered in the text. Age 
classifications may not be uniform and comparability is also hindered by differences in food 
composition tables used for the conversion of food consumption data to nutrient intake data 
(Deharveng et al., 1999). Although these differences have an impact on the accuracy of 
between-country comparisons, the data presented give a rough overview of average vitamin D intakes 
and intakes in high consumers in a number of European countries. 
2.1. Adults 
Mean intakes of vitamin D from foods only varied from 1.1 µg/day (Spain, women, 18-64 years) to 
8.2 µg/day (Finland, men, 25-74 years). The 95
th
 percentiles varied between 2.4 µg/day (Spain, 
women, 18-64 years) and 16.0 µg/day (Finland, men, 25-74 years).  
When foods and supplements were considered together, mean intakes of vitamin D varied from 
3.1 µg/day (Ireland, women, 18-35 years) to 23.5 µg/day (Norway, men in the fourth quartile of 
n-3 long-chain polyunsaturated fatty acid intake, 16-79 years). Intakes at the 95
th
 percentile varied 
between 6.3 µg/day (The Netherlands, women, 19-30 years) and 24.2 µg/day (Ireland, ≥65 years).  
The Panel notes that the range of vitamin D intakes reported from 14 European countries is 
considerable. In high consumers (95
th
 percentile), intakes from foods are up to 16 µg/day, and about 
1.5-fold this value in those that consume supplements in addition to foods.  
2.2. Infants (≤1 year) 
For infants, mean intakes from foods and supplements were available from Finland and The 
Netherlands, and varied between 8.9 µg/day (The Netherlands, 1 year) and 12.5 µg/day (The 
Netherlands, 0.75 years). The 90
th
 percentiles were between 14.8 and 19.3 µg/day in Dutch infants 
aged 1 and 0.75 years, respectively. The high percentiles available for Finland (P75) were within this 
range.  
                                                     
4  Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of 
vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26-38. 
5  Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of 
the Member States relating to food supplements. OJ L 183, 12.07.2002, p. 51-57. 
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2.3. Children (approximately 1-14 years) 
In younger children, mean intakes from foods varied from 1.7 µg/day (Denmark, boys, 1-3 years) to 
5.6 µg/day (Greece, 1-5 years). The values for high percentiles were between 2.4 µg/day (Denmark, 
P95, boys, 1-3 years) and 11.9 µg/day (Greece, P90, 1-5 years). Mean vitamin D intakes from foods 
and supplements varied from 2.3 µg/day (UK, 1.5-3 years) to 9.0 µg/day (Finland, girls, 2 years). The 
90
th
 percentile in Dutch children  aged 1.5 years was 8.1 µg/day. The high percentiles available for 
Finland (P75) were even higher, i.e. 9.5 and 12.6 µg/day in boys and in girls, aged 2 or 3 years. 
In older children, mean or median intakes from foods only varied from 1.4 µg/day (mean, Spain, 
4-10 years; Ireland, boys, 5-12 years) to 2.7 µg/day (The Netherlands, median, boys, 9-13 years). 
Intakes at the 95
th
 percentile were between 2.9 µg/day (Spain, 4-10 years, including fortified food) 
and 5.9 µg/day (Denmark, 4-14 years). Average intakes from foods and supplements varied from 
1.8 µg/day (mean, Germany, 6-11 years; Spain, 4-10 years) to 6.6 µg/day (Sweden, mean, 4 years). 
Intakes at the 95
th
 percentile were between 3.0 µg/day (Spain, 4-10 years) and 15.4 µg/day (Sweden, 
4 years). 
2.4. Adolescents 
In adolescents, mean intakes from foods varied from 1.6 µg/day (Spain, 11-17 years) to 4.0 µg/day 
(Belgium, boys 13-18 years). Intakes at the 95
th
 percentile were between 3.0 µg/day (Spain, 
11-17 years) and 7.7 µg/day (Italy, boys, 10-<18 years, including fortified food). Mean or median 
intakes from foods and supplements and for the 95
th
 percentile of consumption are within these 
ranges. 
The Panel notes that in infants, children and adolescents from 11 European countries, the highest 
intakes from foods and supplements are observed in infants (up to about 19 µg/day at the 
90
th
 percentile), while the intake in high consumers is lower in children (up to about 15 µg/day at the 
95
th
 percentile) and even lower in adolescents (up to about 8 µg/day at the 95
th
 percentile).  
3. Hazard identification 
3.1. Vitamin D physiology 
Vitamin D derives from diet but can also be synthesised in the skin from 7-dehydrocholesterol under 
the influence of UV-B radiation (290–315 nm wavelengths), leading to the formation of 
previtamin D3. Previtamin D3 thermally isomerises to vitamin D3 immediately after formation. 
Sunlight itself regulates the total production of vitamin D3 in the skin, as both previtamin D3 and 
vitamin D3 present in the skin are photodegraded to biologically inert isomers following prolonged 
UV-B exposure. Dietary intake of vitamin D increases 25(OH)D concentrations without an equivalent 
regulatory mechanism, with a linear relationship between vitamin D intakes and serum 25(OH)D 
concentrations well into the high dose range (Holick, 2006). The 24-hydroxylase catabolises 
25(OH)D to 24,25(OH)2D to prevent its eventual activation to 1,25(OH)2D (Jones et al., 2012). 
Following vitamin D supplementation, 24-hydroxylase is upregulated, though this adaptation occurs 
with a lag of several weeks (Wagner et al., 2011).  
Both 25- and 1α -hydroxylation of vitamin D are needed to form the active metabolite 1,25(OH)2D. 
At least four enzymes, all microsomal cytochrome P450 (CYP) isoforms (CYP2DII, CYP2D25, 
CYP3A4, and CYP2R1), can accomplish the 25-hydroxylation of vitamin D in human hepatocytes. 
Little feedback is assumed for these 25-hydroxylases, and serum 25(OH)D concentration generally 
reflects vitamin D status. Serum 1,25(OH)2D, the active metabolite, is synthesised in the kidney, 
where the activity of the enzyme 25(OH)D-1α-hydroxylase (CYP27B1) is regulated by calcium and 
phosphate, as well as by their regulating hormones (calcium, parathyroid hormone, calcitonin, growth 
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hormone, and insulin-like growth factor I being positive regulators; phosphate, fibroblast growth 
factor 23, and 1,25(OH)2D itself being negative regulators). The active metabolite exerts its action 
through binding to the vitamin D receptor and activating a nuclear transcription factor (Bouillon et al., 
2008). 
The principal function of the active metabolite (1,25(OH)2D) is to maintain intracellular and 
extracellular calcium concentrations within a physiologically acceptable range. This regulation is 
accomplished by enhancing the efficiency of the small intestine in absorbing dietary calcium and 
phosphorus, and by mobilising calcium and phosphorus from the bone. 
3.2. Biomarkers of vitamin D intake 
The concentration of 25(OH)D in plasma or serum can only be used as a biomarker of vitamin D 
intake in people with low exposure to sunshine. After initiation of vitamin D supplementation, a new 
steady state is reached after six to eight weeks in adults (Seamans and Cashman, 2009). It has been 
suggested that whereas vitamin D2 and vitamin D3 may equally increase 25(OH)D concentrations 
when supplemented daily, vitamin D3 may raise 25(OH)D concentrations more than vitamin D2 if 
single or infrequent bolus doses are administered (Tripkovic et al., 2012). 
3.3. Biomarkers of vitamin D status and activity 
There is consensus that serum 25(OH)D concentration is a good marker of vitamin D status (Seamans 
and Cashman, 2009). The 25(OH)D denotes both D2 and D3 metabolites. Plasma 
25-hydroxyergocalciferol (25(OH)D2) is of exogenous origin only, while 25-hydroxycholecalciferol 
(25(OH)D3) may arise from either dietary intake or formation in the skin. Plasma concentration of 
1,25(OH)2D (particularly free 1,25(OH)2D) is a measure of vitamin D hormone activity, but because 
of tight homeostatic regulation, 1,25(OH)2D does not reflect vitamin D nutritional status. 
Owing to its slow turnover in the body (half-life of about two months (Jones, 2008), vitamin D is 
often administered weekly in equivalent doses instead of daily. Depending on the dose and the 
duration of supplementation, resulting 25(OH)D concentrations may be comparable (Ish-Shalom et 
al., 2008) or somewhat lower (Chel et al., 2008) with weekly compared to daily supplementation, 
respectively. 
The main determinants, besides intake, of vitamin D status are skin pigmentation and sun exposure. 
Concentrations of 25(OH)D vary according to season, with the lowest concentrations occurring at the 
end of winter and the highest concentrations in summer (Hintzpeter et al., 2008), generally reflecting 
the amount of endogenous synthesis following UV-B radiation. Latitude of residence and time of day 
also determine the amount of UV-B photons penetrating the stratospheric layer and resulting in 
cutaneous synthesis of previtamin D3 in exposed skin (Holick, 2006). Below a latitude of 
approximately 35° North, UV-B radiation is sufficient for vitamin D3 synthesis all year round. At 
higher latitudes, there is no cutaneous vitamin D3 synthesis during the winter months. For example, in 
Rome, Italy (latitude 41.9° North), cutaneous vitamin D3 synthesis is not possible from November 
through February. Ten degrees further north in Berlin, Germany (latitude 52.5° North) or Amsterdam, 
the Netherlands (latitude 52.4° North), vitamin D3 synthesis ceases between October and April 
(Tsiaras and Weinstock, 2011). Vitamin D intoxication by UV-B radiation alone has not been 
reported (Webb et al., 1989). Mean (range) 25(OH)D concentrations under sun-rich living conditions 
were 133 (27-277) nmol/L in 18 farmers in Puerto Rico (Haddock et al., 1982), 161 (132-197) nmol/L 
in eight lifeguards in St. Louis (USA) (Haddad and Chyu, 1971), and 133±84 nmol/L in 44 Israeli 
lifeguards (Better et al., 1980). Following extended exposure to sunlight during summer, median 
(interquartile range) 25(OH)D concentrations in late summer were 122 (95–154) nmol/L in 26 young 
men for whom sun exposure was the principal source of vitamin D, with the highest concentration 
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being 211 nmol/L. The median (interquartile range) seasonal difference in 25(OH)D concentration 
between late summer and late winter was 49 (29-67) nmol/L (Barger-Lux and Heaney, 2002).  
Further determinants of vitamin D status are age and body mass, with lower 25(OH)D concentrations 
observed in advanced age (Hintzpeter et al., 2008; Holick, 2006) and in obesity (Hintzpeter et al., 
2008; Kauppi et al., 2009; Macdonald et al., 2008; Snijder et al., 2005).   
The amount of vitamin D in human milk is modestly correlated with maternal vitamin D intakes up to 
about 18 µg/day, with evidence for a lower response in African-American compared to white women 
(Specker et al., 1985). Few data are available to estimate precisely the increase in human milk 
vitamin D concentration in response to supplemental vitamin D (Ala-Houhala et al., 1986; Hollis and 
Wagner, 2004; Specker et al., 1985). Infants of mothers supplemented with 50 or 100 µg 
vitamin D/day during months 1-4 of lactation only differed slightly in serum 25(OH)D concentration 
(Hollis and Wagner, 2004), pointing to a limitation of vitamin D transfer into human milk.   
3.4. Mechanisms of toxicity 
Following ingestion of large doses of vitamin D, the concentration of 25(OH)D in serum increases, 
while that of the active metabolite 1,25(OH)2D is unchanged (Jones, 2008) or even reduced (IoM, 
2010). However, at high concentrations of 25(OH)D and other vitamin D metabolites (such as 
24,25(OH)2D3, 25,26(OH)2D3, and 25(OH)D3-26,23-lactone) the binding capacity of the vitamin D 
binding protein may be exceeded, leading to the release of unbound 25(OH)D and 1,25(OH)2D. It has 
been hypothesised that these free forms enter target cells and directly stimulate gene transcription 
(Bouillon et al., 2008). However, severe hypercalcaemia and weight loss after administration of 
vitamin D have been observed in a mouse model which is unable to synthesise 1,25(OH)2D, 
suggesting that 25(OH)D rather than 1,25(OH)2D may be mediating toxicity (DeLuca et al., 2011). 
Very high serum 25(OH)D concentrations (which may displace 1,25(OH)2 D from vitamin D-binding 
protein) may lead to hypercalcaemia (Holick, 2006; Pettifor et al., 1995; Vieth, 1990), which is 
defined by serum calcium concentrations >2.75 mmol/L (11 mg/dL). Values used for the diagnosis of 
hypercalcaemia may change across laboratories and will be defined in this opinion according to the 
cut-off selected by the authors in each individual study. Clinical symptoms associated with 
hypercalcaemia are fatigue, muscular weakness, anorexia, nausea, vomiting, constipation, tachycardic 
arrhythmia, soft tissue calcification, failure to thrive, and weight loss. Hypercalcaemia may also lead 
to hypercalciuria, which is defined by a calcium excretion >0.3 mg/mg creatinine in 24-hour urine of 
adults, or as a calcium excretion >250 mg/day in women and >275-300 mg/day in men. Consequences 
of sustained hypercalcaemia are nephrolithiasis (kidney stones), nephrocalcinosis, and a decrease in 
kidney function (see also the Scientific Opinion on the Tolerable Upper Intake Level of calcium 
(EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2012). 
3.5. Adverse effects of excess vitamin D intake 
3.5.1. Vitamin D intake and hypercalcaemia in adults 
In 2003, the SCF derived a UL of 50 µg vitamin D/day for adults (SCF, 2003). In this section, new 
evidence which has become available since 2003 will be described in conjunction with the evidence 
used to derive the previous NOAEL of 100 µg vitamin D/day for adults. Intervention studies in which 
vitamin D was administered weekly or more frequently in doses equivalent to intakes between 60 and 
1,269 µg/day, and which reported on serum calcium concentrations and/or the occurrence of 
hypercalcaemia, have been considered (see also Appendix C). 
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Studies with vitamin D doses up to 275 µg/day 
A number of intervention studies in humans have reported on the effects of vitamin D 
supplementation at doses up to 275 µg/day on calcaemia and calciuria (Appendix C). Several studies 
monitored serum calcium concentrations at several time points throughout the study and addressed 
possible adverse effects as secondary outcomes. The majority of the studies were randomised 
controlled trials (RCTs) in which vitamin D supplementation was compared to a placebo (Aloia et al., 
2008; Gallagher et al., 2012; Heaney et al., 2003; Jorde et al., 2010; Sneve et al., 2008; Zittermann et 
al., 2009) or to a lower dose of vitamin D (Grimnes et al., 2012; Narang et al., 1984; Vieth et al., 
2001). One was a dose-response study using four different doses of vitamin D in the range of 
0-275 g/day (Heaney et al., 2003). One controlled study was not randomised (Berlin et al., 1986; 
Berlin and Björkhem, 1987), one was a two-arm intervention with no control group (Tjellesen et al., 
1986), and one was a one-arm intervention with no control group (Mocanu et al., 2009). Considering 
only the highest dose in studies using multiple doses, the equivalent daily vitamin D doses ranged 
from 83 to 275 µg, and the duration of the supplementation from seven weeks to 12 months. In 
addition to vitamin D, subjects received supplemental calcium in five studies: four studies used doses 
ranging from 320 to 1,000 mg/day (Grimnes et al., 2012; Jorde et al., 2010; Mocanu et al., 2009; 
Tjellesen et al., 1986), while supplemental calcium intake was adjusted individually to achieve a total 
calcium intake of 1,200-1,400 mg/day in the study by Gallagher et al. (2012). The shorter-term studies 
were generally performed in seasons of low sun exposure. Study populations were not generally 
vitamin D-deficient, and two studies (Grimnes et al., 2012; Heaney et al., 2003) were conducted in 
subjects with a high vitamin D status at baseline. Study populations included whites, African 
Americans, young men, pre- and postmenopausal women, elderly nursing home residents, and 
overweight and obese adults.  
The study by Narang et al. (1984) reported mean serum calcium concentrations to be slightly above 
the normal range in the few subjects who received the highest vitamin D dose (95 µg/day). The Panel 
notes that these results are not in line with the findings of studies using similar or (much) higher doses 
of vitamin D. The Panel also notes that this study did not include a true (non-vitamin D) control 
group, and that no information on serum 25(OH)D concentration, season of the trial, background 
vitamin D intake and persistance of elevated serum calcium concentration was provided.  
In the dose-response study by Heaney et al. (2003), in which men received either 0, 20.9, 137.5 or 
275 µg vitamin D3/day for 20 weeks, mean serum calcium concentrations measured at five time points 
during the study in the two groups receiving the highest doses of vitamin D did not change 
significantly from baseline and remained below the upper limit of normal (<2.6 mmol/L) for all of the 
31 subjects in these groups. 
None of the remaining studies reported persisting or occasional hypercalcaemia and/or hypercalciuria 
which could be attributed to vitamin D supplementation. The Panel notes that several studies used 
doses of vitamin D >95 g/day.  
The Panel concludes that vitamin D at doses up to 275 µg/day do not lead to persisting 
hypercalcaemia or hypercalciuria in adults. 
Studies with vitamin D doses >275 µg/day 
In an open-label study, Barger-Lux et al. (1998) administered 35, 234 or 1,269 g vitamin D3/day for 
eight weeks to 38 men (n=14 in the highest dose group). The authors stated that post-treatment testing 
indicated absence of hypercalcaemia in vitamin D3-supplemented subjects, but no further information, 
including a definition of hypercalcaemia, was given. The Panel notes that the serum concentrations of 
25(OH)D reported in this study for the highest dose group (about 710 nmol/L) were far above those 
observed following considerable sun exposure (serum 25(OH)D concentration between around 
120 and 160 nmol/L, see Section 3.3).  
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Hypercalcaemia owing to high intakes of vitamin D in dietary supplements (e.g. Araki et al. (2011); 
Lowe et al. (2011)) or in milk (Blank et al., 1995; Jacobus et al., 1992) has been reported. Doses of 
vitamin D and duration of supplementation cannot be estimated precisely from these case reports.  
In some studies, higher doses of vitamin D (twice weekly administration equivalent to 321 µg 
vitamin D2/day, 450 µg vitamin D2/day) were part of the treatment regimen for various diseases, and 
its use for weeks to years was not associated with increased serum calcium concentrations or 
hypercalcaemic episodes (Hasling et al., 1987; Rickers et al., 1982). However, these findings are 
difficult to interpret because of the concomitant administration of substances that may have 
confounded the outcome (e.g. prednisone and/or sodium fluoride), and because of the use in small 
groups of patients with various diseases. For the same reasons, evidence from case reports of 
vitamin D intoxication after administration of vitamin D for the treatment of osteoporosis, 
osteomalacia, hypoparathyroidism or other diseases (Davies and Adams, 1978; Rizzoli et al., 1994; 
Schwartzman and Franck, 1987; Selby et al., 1995) (see Appendix C) cannot be used for the 
establishment of a UL for healthy adults. 
The Panel notes that the data available from these studies and case reports on vitamin D at intakes 
>275 µg/day are not suitable for establishing a UL for long-term intakes.  
3.5.2. Serum 25(OH)D concentration and hypercalcaemia in adults 
Following supplementation with up to 275 µg vitamin D3/day for 20 weeks, Heaney et al. (2003) 
observed a mean 25(OH)D concentration of about 220 nmol/L without concomitant hypercalcaemia.  
Vieth (1999) reviewed case reports of vitamin D toxicity and concluded that hypercalcaemia owing to 
vitamin D intoxication per se is always accompanied by serum 25(OH)D concentrations >220 nmol/L. 
Other reviews suggested that hypercalcaemia only resulted at 25(OH)D concentrations consistently 
exceeding 375-500 nmol/L (Jones, 2008), or ≥700 nmol/L in normal adults (Hathcock et al., 2007). In 
four cases of vitamin D intoxication in osteoporotic women, 25(OH)D concentrations between 
339 and 804 nmol/L were observed during the course of diagnosis and treatment (Schwartzman and 
Franck, 1987). Araki et al. (2011) reported hypercalcaemia in two cases of vitamin D intoxication 
following ingestion of erroneously manufactured and labelled vitamin D supplements; both patients 
became normocalcaemic and asymptomatic once 25(OH)D concentrations decreased below 
998 nmol/L. In 19 case reports on hypercalcaemia, serum 25(OH)D concentrations of 
533-1,692 nmol/L were reported after a daily vitamin D intake between 1,250 µg and 7,500 µg for 
three weeks to several years (Davies and Adams, 1978; Rizzoli et al., 1994; Selby et al., 1995); 
however, one woman who presented with hypercalcaemia after receiving the equivalent of 2,143 µg 
vitamin D3/day for 96 weeks had a plasma 25(OH)D concentration of only 221 nmol/L (Rizzoli et al., 
1994). 
The Panel concludes that 25(OH)D concentrations associated with hypercalcaemia vary over a wide 
range, and that the 25(OH)D concentration in serum or plasma cannot be considered a suitable 
predictor of hypercalcaemia.  
3.5.3. Vitamin D intake or status and long-term health outcomes in adults 
A wealth of observational and intervention studies has been performed in recent years on the 
association between vitamin D intake or status and various chronic diseases. The studies generally 
adjusted for season. Most of the observational studies (Anderson et al., 2010; Cawthon et al., 2010; 
Eaton et al., 2011; Ford et al., 2011; Ginde et al., 2009; Hutchinson et al., 2010; Jia et al., 2007; 
Semba et al., 2009; Semba et al., 2010; Virtanen et al., 2011; Visser et al., 2006) aimed at evaluating 
the role of vitamin D insufficiency as a risk factor, but some also took into account potential adverse 
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effects of high serum 25(OH)D concentrations or high vitamin D intake and allowed for non-linear 
associations when analysing relationships.  
Of these, some observational studies found a U-shaped or reverse J-shaped association between 
25(OH)D concentrations and all-cause mortality, with a significant increase in risk in elderly Swedish 
men with concentrations >98 nmol/L (but not >93 nmol/L) (Michaelsson et al., 2010) and in US 
females (but not in men or both sexes combined) with concentrations >124.8 nmol/L (Melamed et al., 
2008). In some studies, the higher risk associated with the highest 25(OH)D concentrations did not 
hold for longer times of follow-up (Johansson et al., 2011) or did not consider important possible 
confounders such as smoking, body mass index (BMI) and health status (Durup et al., 2012). 
Evidence from a meta-analysis of randomised primary and secondary prevention trials which provided 
data for mortality analyses showed that a dose ≥20 µg vitamin D3/day (n=21 studies) or ≥20 µg 
vitamin D2/day (n=12 studies) administered over a median of two years did not affect all-cause 
mortality (Bjelakovic et al., 2011). These results are in line with findings of another meta-analysis 
that did not observe an effect of vitamin D doses ≥20 µg/day on mortality as observed in 
20 randomised trials (Elamin et al., 2011). 
Some studies performed subgroup analyses according to the cause of death. A significant increase in 
total cancer mortality was observed in Swedish elderly men with baseline serum 25(OH)D 
concentrations >98 nmol/L (but not >93 nmol/L) (Michaelsson et al., 2010), and in US men (but not 
in women) with 25(OH)D concentrations in the highest two categories (80-<100 nmol/L and 
≥100 nmol/L) compared to men with 25(OH)D concentrations <37.5 nmol/L, though the overall trend 
was not significant (Freedman et al., 2010). In other cohort studies (Cawthon et al., 2010; Eaton et al., 
2011; Hutchinson et al., 2010; Melamed et al., 2008), either no association or an inverse association 
between 25(OH)D concentration and risk for mortality from cancer was reported. A meta-analysis of 
observational studies published up to July 2011 showed no association between 25(OH)D 
concentration and breast cancer (five studies) or prostate cancer (11 studies), and an inverse 
association with colorectal cancer (nine studies) (Chung et al., 2011). In RCTs using vitamin D doses 
between 10 and 27.5 µg/day and lasting four to seven years in which cancer of the breast or colon 
were secondary outcomes, there was no evidence of an increased cancer risk in subjects receiving 
vitamin D (Chlebowski et al., 2008; Lappe et al., 2007; Wactawski-Wende et al., 2006). In a nested 
case-control study with participants from eight prospective cohorts, there was a significantly 
increased risk for pancreatic adenocarcinomas for subjects with 25(OH)D concentrations 
≥100 nmol/L, but the risk pattern was rather peculiar with a flat trend line (risk close to 1 in all other 
categories of 25(OH)D concentration) followed by a steep inflection for the subjects in the highest 
category (Stolzenberg-Solomon et al., 2010). In two US cohorts for which only intake data were 
available, the association between vitamin D intake and pancreatic cancer was inverse (Skinner et al., 
2006).   
Several studies also addressed the relationship between 25(OH)D concentration and cardiovascular 
disease, but no evidence of an increased risk for fatal and non-fatal cardiovascular events associated 
with high concentrations of 25(OH)D was found in observational studies (Cawthon et al., 2010; Eaton 
et al., 2011; Fiscella and Franks, 2010; Grandi et al., 2010; Hutchinson et al., 2010; Jassal et al., 2010; 
Michaelsson et al., 2010; Virtanen et al., 2011). 
On other health outcomes, an observational study reported a significantly increased risk for 
self-reported fractures in black women with 25(OH)D concentrations ≥49.9 nmol/L (compared to 
<49.9 nmol/L), whereas the association was inverse for white women (Cauley et al., 2011). In women 
receiving 1 g calcium plus 10 µg vitamin D daily for a mean of seven years, a higher incidence of 
self-reported urinary tract stones was reported compared to those receiving placebo (Wallace et al., 
2011). Plasma or serum 25(OH)D concentrations were not measured in this study. The Panel notes 
that the low dose of vitamin D used, and the nature of the combined nutrient supplementation, do not 
allow the attribution of the reported adverse effect to vitamin D intake per se. 
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The Panel notes that no studies reported an association between vitamin D intake and increased risk 
for adverse long-term health outcomes, and that studies reporting on an association between 25(OH)D 
concentration and all-cause mortality or cancer are inconsistent. The Panel also notes that when 
25(OH)D concentrations were associated with an increased risk for adverse long-term health 
outcomes in some studies, there was a wide variation in 25(OH)D concentrations associated with the 
adverse effect. The Panel considers that 25(OH)D concentrations cannot be used to characterise the 
risk for adverse long-term health outcomes.  
3.5.4. Adverse effects of vitamin D intake in pregnant and lactating women 
De-Regil et al. (2012) systematically searched the literature for RCTs which evaluated the effect of 
supplementation with vitamin D alone or in combination with calcium on women during pregnancy. 
Six RCTs published up to October 2011 were included for meta-analysis. The dose of vitamin D used 
in routine daily supplementation ranged from 20-30 µg. The studies reported on pre-eclampsia, 
nephritic syndrome, and stillbirths or neonatal deaths, and there was no difference in risk between 
pregnant women receiving vitamin D and those receiving placebo. 
Hollis et al. (2011) randomly assigned pregnant women to receive either 10 µg, 50 µg or 100 µg 
vitamin D3/day from 12-16 weeks of gestation until delivery. The primary outcome was change in 
maternal serum 25(OH)D concentrations, but the study also addressed the safety of vitamin D 
supplementation and pregnancy outcomes. Of the 502 women randomised, only 350 were followed 
through delivery, and no attempt was made to assess pregnancy outcomes in those who discontinued 
from the study for reasons other than miscarriage. The number of, and gestational age at, pregnancy 
losses, and the serum 25(OH)D concentrations in those affected, did not differ between the groups 
(n=8, 5, 10 in the groups receiving 10 µg, 50 µg or 100 µg vitamin D3/day, respectively). Mode of 
delivery, pregnancy duration, birth weight and neonatal level of care required after birth also did not 
differ. No information on the nature of adverse events was given in the study, but the authors stated 
that no adverse event was attributed to vitamin D supplementation or serum 25(OH)D concentrations. 
Throughout the trial, the groups did not differ with respect to serum calcium and urinary 
calcium-to-creatinine ratio. It was decided a priori to discontinue supplementation in women 
exceeding a 25(OH)D concentration of 225 nmol/L as a safety measure. Three women (one in the 
100 µg vitamin D3/day group) attained this threshold without accompanying hypercalcaemia or 
hypercalciuria.  
In another study, lactating women (n=18) randomly received either 40 µg vitamin D2+10 µg 
vitamin D3/day or 90 µg vitamin D2+10 µg vitamin D3/day from month 1 through 4 of lactation during 
which time they were asked to limit sun exposure (Hollis and Wagner, 2004). Serum calcium 
concentrations remained within the normal range and hypercalciuria did not occur. Serum 25(OH)D 
concentrations increased from 69±8 to 90±6 nmol/L in the group receiving 40 µg vitamin D2+10 µg 
vitamin D3/day and from 82±6 to 111±10 nmol/L in the group receiving 90 µg vitamin D2+10 µg 
vitamin D3/day. In the infants, concurrent increases in serum 25(OH)D concentration were observed 
resulting from an increase in vitamin D intake via human milk. In infants whose mothers received the 
lower vitamin D dose, total circulating 25(OH)D concentrations increased from 20±3 to 
69±10 nmol/L, whereas concentrations increased from 33±8 to 77±12 nmol/L in infants of mothers 
receiving the higher vitamin D dose.   
In a nested case-control study, a U-shaped association was observed in white (n=77 cases, 
196 controls) but not in black (n=34 cases, 105 controls) nulliparous women between 25(OH)D 
concentrations in the first half of pregnancy (<22 weeks) and birth of a small-for-gestational age 
(SGA) infant (Bodnar et al., 2010). In white women, the odds ratio (OR) was 2.1 (95 % CI 1.2-3.8) 
for a serum 25(OH)D concentration >75 nmol/L (reference category 37.5-75 nmol/L). The Panel 
notes that it is unclear whether a one-time measurement of vitamin D status in early pregnancy 
reflects vitamin D status throughout pregnancy, that no intake data are available linking vitamin D 
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intake to an increased risk for an SGA infant, and that only a limited number of possible dietary and 
lifestyle confounders were taken into account in the analyses. Thus, the Panel considers that no 
conclusions can be drawn from this study in relation to the effects of vitamin D intake on pregnancy 
outcomes.  
The Panel considers that evidence from one intervention trial in pregnant women receiving vitamin D 
after the period of early organogenesis and from another small trial in lactating women, both using 
doses of vitamin D2 or D3 up to 100 µg/day for several weeks to months, did not report adverse events 
for either the mothers or their offspring.   
3.5.5. Adverse effects of vitamin D intake in infants 
In infants, hypercalcaemia has been associated with single large dose therapies of vitamin D (also 
known as stoss therapy). The potential toxicity associated with stoss therapy is underscored by a 
report showing hypercalcaemia in a young child who received the equivalent of four daily stoss 
therapy doses of 15 mg vitamin D each (Barrueto et al., 2005). The Panel notes that no information on 
effects of chronic daily intake relevant for the establishment of a UL can be derived from such case 
reports.  
A number of studies with lower daily doses of vitamin D are available. 
Jeans and Stearns (1938) found retarded linear growth in nine infants up to one year of age who 
received about 45-112.5 g vitamin D/day in comparison with standard growth curves of infants 
receiving daily vitamin D at doses of 8.5 g or less for a minimum of six months. The infants were 
given either cod liver oil, a cod liver oil concentrate emulsified in cream, or viosterol (vitamin D2) in 
oil. The infants supplemented with high doses of vitamin D showed retarded linear growth, and 
increased rates of growth were seen when the dose of vitamin D was reduced to 10-15 g/day. In 
another study, Fomon et al. (1966) compared 13 formula-fed infants who ingested 34.5-54.3 g 
vitamin D/day (median intake 45 g/day) with 11 infants who ingested 8.8-13.8 g/day (median 
intake 11 µg/day). The infants were enrolled before the age of nine days and were followed-up at ages 
28, 56, 84, 112, 140 and 168 days. A group of 26 breast-fed infants was also followed. No differences 
in linear growth and in serum calcium concentrations were found between groups in this small study. 
Data from a Finnish population-based birth cohort was used to assess retrospectively the association 
between infantile vitamin D supplementation and body height at various time points until adulthood 
(Hyppönen et al., 2011). No association of vitamin D dose (<50 µg/day, n=66; 50 µg/day according to 
the Finnish recommendations at that time, n=8,100; and >50 µg/day, n=407) in regularly 
supplemented infants with body length or height at one year (measured), at 14 years (self-reported) 
and in adulthood (self-reported and measured) was reported. No difference in height was observed 
between groups classified according to frequency of supplementation (none, irregular, or regular), but 
again the groups were highly unequally sized. 
In a study from Finland, Ala-Houhala (1985) supplemented breast-fed infants with 0, 10 or 25 g 
vitamin D2/day for 20 weeks (14-17 infants per group). Mothers of infants not taking vitamin D 
received 25 g/day. Two studies were conducted, one starting in January and the other starting in 
July. Mean serum calcium concentrations in infants did not appear to increase throughout the study in 
either group.  
Vervel et al. (1997) studied healthy neonates born from April to July of mothers supplemented (n=22) 
or not supplemented (n=48) with vitamin D during pregnancy. The infants were given supplemental 
vitamin D2 (either 12.5 or 25 µg/day). In addition, they were fed infant formulae chosen by the 
mothers and thus varying slightly in vitamin D content (10.7±1.2 µg/L). All 70 infants were followed 
until the age of one month, and 52 infants were followed until three months of age. Mean serum 
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calcium concentrations did not differ between groups at one and three months of age. Serum calcium 
concentrations at three months ranged from 2.42 to 2.80 mmol/L in infants who received 12.5 µg 
vitamin D/day in addition to fortified infant formula, and from 2.46 to 2.79 mmol/L in those 
supplemented with 25 µg vitamin D/day; the percentage of infants presenting with serum calcium 
concentrations >2.6 mmol/L was lower in the higher vitamin D group compared to the lower 
vitamin D group. 
In a randomised study, infants and toddlers with hypovitaminosis D (25(OH)D concentration 
<50 nmol/L) aged between 9 and 23 months were treated for six weeks with either 50 µg vitamin D2 
daily (n=12), 1,250 µg vitamin D2 weekly (n=14), or 50 µg vitamin D3 daily (n=14), and each group 
also received 50 mg calcium/kg body weight per day (Gordon et al., 2008). Small and similar changes 
in mean serum calcium concentrations in the three treatment groups (-3 % for vitamin D2 daily, +3 % 
for vitamin D2 weekly, +1 % for vitamin D3 daily) were reported, as well as a higher overall incidence 
of mild hypercalcaemia at baseline compared to after treatment, but no definition was given as to the 
normal range of calcium concentrations in serum. All subjects with mild hypercalcaemia were 
reported to be asymptomatic. The Panel notes that this was a short study using high vitamin D doses 
for treatment of deficiency, and considers that limited conclusions can be drawn from this study for 
the purpose of this risk assessment. 
The Panel notes that there is historical evidence on retarded growth from one study in infants who 
received various regimens of vitamin D exceeding 45 µg/day up to one year of age, although another 
small study using doses up to 54 µg vitamin D/day until about five months of age did not show such 
an effect. More recent intervention studies using doses up to 25 µg vitamin D/day (plus the amount 
ingested via fortified infant formula) for up to five months after birth did not indicate that these 
intakes were associated with hypercalcaemia in infants. 
3.5.6. Vitamin D intake and hypercalcaemia in children and adolescents 
Two intervention studies on the effects of vitamin D supplementation on calcaemia in children and 
adolescents from the same geographical area are available in the literature. 
In a randomised “pilot” study, boys and girls aged 10-17 years received for eight weeks starting in 
August either placebo oil (n=9), weekly amounts of 350 µg vitamin D3 as oily preparation (n=8) or 
the same amount of vitamin D3 dissolved in ethanol (n=9). After eight weeks, two boys in the placebo 
group had elevated serum calcium concentrations, and one girl who had received vitamin D3 dissolved 
in ethanol had high concentrations of both serum 25(OH)D and serum calcium (195 nmol/L and 
2.7 mmol/L, respectively). As serum calcium only slightly exceeded the upper limit of normal for that 
age (2.68 mmol/L), the authors did not consider this as evidence for vitamin D intoxication. Two 
other subjects with high 25(OH)D concentrations (>150 nmol/L) did not have concomitantly elevated 
serum calcium concentrations (Maalouf et al., 2008). 
In a second study by the same authors, healthy girls (n=168) and boys (n=172) aged 10-17 years from 
Beirut (latitude 33.5° North) randomly received weekly either 35 µg vitamin D3 (equivalent to 
5 µg/day), 350 µg vitamin D3 (equivalent to 50 µg/day) or placebo for one year (El-Hajj Fuleihan et 
al., 2006; Maalouf et al., 2008). The primary outcomes were changes in lean mass, bone mineral 
density and bone mineral content. Hypercalcaemia did not occur in the girls who received vitamin D3. 
Three girls (5 %) in the high-dose group had high serum 25(OH)D concentrations at the end of the 
study (257, 402 and 487 nmol/L), but none had concomitant hypercalcaemia (>2.68 mmol/L). Two 
boys (4 %) in the high-dose group had high serum 25(OH)D concentrations at the end of the study 
(157 and 172 nmol/L), but none had concomitant hypercalcaemia. Five boys, of whom three had 
received placebo, one the low and one the high vitamin D dose, had hypercalcaemia. Thus, as cases of 
hypercalcaemia occurred in active and non-active treatment groups, these cases cannot be related to 
supplementation with vitamin D per se. Calcium intake and sun exposure, but not dietary intake of 
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vitamin D, were measured at baseline and follow-up, but were not reported in relation to adverse 
events.  
The Panel notes that there are only two studies on weekly vitamin D supplementation equivalent to 
daily intakes of 5-50 µg in children and adolescents, and that the mild hypercalcaemia observed in a 
few subjects could not be attributed to vitamin D supplementation. The Panel concludes that 
vitamin D intakes at doses up to 50 µg/day do not lead to hypercalcaemia in children and adolescents 
aged 10-17 years. 
4. Dose-response assessment and derivation of a Tolerable Upper Intake Level 
The critical effect of excess intake of vitamin D leading to hypervitaminosis D or vitamin D toxicity is 
hypercalcaemia. Hypercalciuria can be associated with hypercalcaemia, but it can also occur without.  
4.1. Adults 
Doses of 234-275 µg vitamin D3/day were administered in two studies to 10-15 healthy men for eight 
weeks to about five months without reported hypercalcaemia (Barger-Lux et al., 1998; Heaney et al., 
2003). The Panel considers that a daily vitamin D dose of 250 µg/day (range 234-275 µg/day) reflects 
a NOAEL. The Panel notes that there are a number of uncertainties on whether this estimate of the 
NOAEL covers the range of variation in the sensitivity of the population to possible adverse effects of 
vitamin D over the long term and that it is based only on two studies of short duration (up to five 
months) in small samples of healthy young men with minimal sun exposure. The Panel considers that 
an uncertainty factor of 2.5 is appropriate to take into account these uncertainties.  
Based on a NOAEL of 250 µg/day (range 234-275 µg/day) and the use of an uncertainty factor of 2.5, 
the UL for adults is estimated at 100 µg/day. Supportive evidence for a UL of 100 µg/day is provided 
by randomised controlled studies in which this dose or higher doses were administered to various 
population groups (whites, African Americans, pre- and postmenopausal women, elderly nursing 
home residents, overweight and obese adults, pregnant and lactating women) for up to 12 months 
without evidence of (persisting) hypercalcaemia or hypercalciuria.   
4.2. Pregnant and lactating women 
There is no evidence that pregnancy or lactation increase the susceptibility for adverse effects of 
vitamin D intake. The Panel considers that the UL of 100 µg/day for adults also applies to pregnant 
and lactating women. This UL is supported by two studies in pregnant and lactating women, both 
using doses of vitamin D2 or D3 up to 100 µg/day for several weeks to months, which did not report 
adverse events for either the mothers or their offspring (Hollis and Wagner, 2004; Hollis et al., 2011). 
4.3. Infants 
For infants, there is still a paucity of data on which to base a NOAEL or a lowest observed adverse 
effect level (LOAEL). The inconsistent evidence on linear growth from two rather old studies with 
low numbers of infants has been complemented by retrospective data on linear growth from infants in 
Finland (Hyppönen et al., 2011). Other studies on the relationship between vitamin D intake and 
linear growth in infants were not available. 
No new data from intervention studies on hypercalcaemia in healthy infants have emerged since the 
risk assessment undertaken by the SCF in 2003.  
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Considering the limited evidence that has become available since the last risk assessment (SCF, 
2003), the Panel considers that the UL of 25 µg vitamin D/day previously derived for infants from 
0-12 months of age should be retained. 
4.4. Children and adolescents 
Since the previous risk assessment (SCF, 2003), two studies in children aged 10-17 years have 
become available (El-Hajj Fuleihan et al., 2006; Maalouf et al., 2008). These studies show that 
vitamin D intakes at doses up to 50 µg/day do not lead to hypercalcaemia in children and adolescents 
aged 10-17 years. While there are no studies at higher intakes, the Panel considers that there is no 
reason to believe that adolescents in the phase of rapid bone formation and growth have a lower 
tolerance for vitamin D compared to adults. Thus, the Panel proposes a UL for vitamin D of 
100 µg/day for adolescents aged 11-17 years. 
For children aged 1-10 years, no new data from intervention studies have emerged since the last risk 
assessment (SCF, 2003). The Panel considers that there is no reason to believe that children aged 
1-10 years in the phase of rapid bone formation and growth have a lower tolerance for vitamin D 
compared to adults, and proposes a UL for vitamin D of 50 µg/day by taking into account their 
smaller body size. 
4.5. Summary of Tolerable Upper Intake Levels for vitamin D 
Age (years) Tolerable Upper Intake Level (UL) for vitamin D ( g/day) 
Children  
  0-1   25 
  1-10   50 
11-17 100 
Adults
1
 ≥18 100 
1 The UL for adults also applies to pregnant and lactating women. 
5. Characterisation of the risk 
Data from European populations indicate that vitamin D intakes from all sources in high consumers 
are below the UL for all population subgroups (i.e., about 25 %, 75 %, 30 % and 8 % of the UL for 
adults, infants, children and adolescents, respectively).  
CONCLUSIONS  
The UL for vitamin D for adults, including pregnant and lactating women, has been established at 
100 µg/day. For children and adolescents, the UL has been set at 50 µg/day for ages 1-10 years, and at 
100 µg/day for ages 11-17 years. For infants up to one year of age, the UL is 25 µg/day.  
Data from European populations indicate that vitamin D intakes from all sources in high consumers 
are below the UL for all population subgroups.   
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APPENDICES 
A.  INTAKE OF VITAMIN D AMONG ADULTS IN EUROPEAN COUNTRIES 
Nutrient 
source Sex Country Reference Dietary assessment method n 
 
Age 
min  
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded Mean Median P75 P95 P97.5 
Foods Women Austria (Elmadfa et al., 
2009b) 
24-hour recall 426 < 25 > 35 Pregnant women in 2nd trimester 2.5     
     76 < 25  25 Pregnant women in 2nd trimester 2.1     
     288  25  35 Pregnant women in 2nd trimester 2.6     
     62  35 > 35 Pregnant women in 2nd trimester 3.3     
  Denmark (Pedersen et al., 
2010) 
7-day record (data collected in 2003-2008) 150  18  24  2.6   7.0  
     340  25  34  2.8   7.6  
     412  35  44  2.9   8.6  
     359  45  54  3.1   9.1  
     326   55   64  3.4     8.4   
     198   65   75  3.4     8.5   
   (Tetens et al., 
2011) 
7-day record and interview (data collected in 
2000-2004) 
671  18  49 Non-supplement users 2.0   7.3  
     825  18  49 Supplements users 2.1   7.7  
     280   50   75 Non-supplement users 2.3     7.7   
     599   50   75 Supplements users 2.5     7.9   
  Finland (Paturi et al., 
2008) 
48-hour recall and two 3-day records for the 
usual intakes over the past year (assessment 
of underreporters) 
641  25  74 Usual intakes. Underreporters 
excluded 
6.0   10.8  
  Germany (MRI, 2008) 24-hour recall + Dietary History 510  19  24  2.0   4.8  
     972  25  34  2.6   6.4  
     2,694  35  50  2.7   6.3  
     1,840   51   64   3.4     8.8   
     1,562   65   80   3.4     8.2   
  Ireland (IUNA, 2011) 4-day record 255  18  35  2.4   5.8 7.9 
     232  36  50  2.8   7.4 8.5 
     153   51   64   3.3     8.1 10.1 
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Nutrient 
source Sex Country Reference Dietary assessment method n 
 
Age 
min  
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded Mean Median P75 P95 P97.5 
Foods Women Italy (Sette et al., 2010) Consecutive 3-day food record 1,245  18 < 65 Including fortified food 2.3   7.3  
     316   65   99 Including fortified food 1.8     6.2   
  Poland (Flynn et al., 
2009) 
24-hour recall 1,656  18  96  3.3   7.9  
  Spain (Flynn et al., 
2009) 
Two non-consecutive 24-hour recalls (one 
for all, a second for 62 % of the sample) 
895  18  64 Data collected in Catalonia. 1.1   2.4  
  Sweden (Becker and 
Pearson, 2002) 
7-day record 67  17  24  4.1   7.6  
     128  25  34  4.5   7.5  
     143  35  44  4.7   8.1  
     118  45  54  5.0   9.1  
     68   55   64   5.8     9.8   
     65   65   74   6.1     10.6   
  The 
Netherlands 
(van Rossum et 
al., 2011) 
Two non-consecutive 24-hour dietary recalls 347  19  30   2.6  4.9  
     351  31  50   2.8  5.3  
     353   51   69     3.2   5.8   
Foods Men Denmark (Pedersen et al., 
2010) 
7-day record (data collected in 2003-2008) 105   18   24   2.6     5.9   
     234  25  34  3.5   8.6  
     318  35  44  3.8   10.4  
     336  45  54  3.7   9.9  
     336   55   64   4.4     11.5   
     240   65   75   3.9     9.9   
   (Tetens et al., 
2011) 
7-day record and interview (data collected in 
2000-2004) 
663  18  49 Non supplement users 2.7   n.a.  
     587  18  49 Supplements users 2.8   9.5  
     363   50   75 Non supplement users 2.9     9.4   
     491   50   75 Supplements users 3.1     9.8   
Tolerable Upper Intake Level of vitamin D 
 
EFSA Journal 2012;10(7):2813 29 
Nutrient 
source Sex Country Reference Dietary assessment method n 
 
Age 
min  
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded Mean Median P75 P95 P97.5 
Foods Men Finland (Paturi et al., 
2008) 
48-hour recall and two 3-day records for the 
usual intakes over the past year (assessment 
of underreporters) 
637  25  74 Usual intakes. Underreporters 
excluded 
8.2   16.0  
  Germany (MRI, 2008) 24-hour recall + Dietary History 510  19  24  3.0   7.0  
     690  25  34  3.5   8.0  
     2,079  35  50  3.8   9.7  
     1,633   51   64   4.2     10.9   
     1,469   65   80   4.4     10.6   
  Ireland (IUNA, 2011) 4-day record 276  18  35  3.1   7.8 9.0 
     205  36  50  3.4   8.3 9.8 
     153   51   64   4.1     10.8 15.6 
  Italy (Sette et al., 2010) Consecutive 3-day food record 1,068  18 < 65 Including fortified food 2.6   7.7  
     202   65   99   2.5     7.5   
  Poland (Flynn et al., 
2009) 
24-hour recall 1,324  18  96  5.7   14.8  
  Spain (Flynn et al., 
2009) 
Two non-consecutive 24-hour recalls (one 
for all, a second for 62 % of the sample) 
718  18  64 Data collected in Catalonia. 1.5   3.1  
  Sweden (Becker and 
Pearson, 2002) 
7-day record 67  17  24  5.6   11.1  
     128  25  34  5.6   9.8  
     143  35  44  6.1   11.3  
     118  45  54  6.6   12.1  
     68   55   64   6.6     13.2   
     65   65   74   7.1     12.1   
  The 
Netherlands 
(van Rossum et 
al., 2011) 
Two non-consecutive 24-hour dietary recalls 356  19  30   3.5  6.1  
     348  31  50   3.8  6.6  
          351   51   69     4.1   7.0   
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Nutrient 
source Sex Country Reference Dietary assessment method n 
 
Age 
min  
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded Mean Median P75 P95 P97.5 
Foods Men and 
women 
France (Dufour et al., 
2010) 
7-day record 1,918  18  79 Non under-reporters. Fortified food 
excluded. 
2.6   5.5 6.7 
  Ireland (IUNA, 2011) 4-day record 226   65 > 65   3.8     9.4 12.0 
  Portugal (Lopes et al., 
2006) 
Food frequency questionnaire 478  18  39 Data collected in Porto 3.7   6.6  
     537  40  49  3.6   6.3  
     789   50   64   3.7     6.4   
     585   65 > 65   3.3     6.1   
  United 
Kingdom 
(Bates et al., 
2011) 
4-day record 807  19  64  2.9    8.5 
     224   65 > 65   3.3       9.0 
Supplements Women Austria (Elmadfa et al., 
2009b) 
Quantitative consumption frequency 
questionnaire 
22   18   65 Assessment of supplement 
consumption among 282 adults in 
all Austria (77 supplement users) 
  5.0 5.0     
  Germany (MRI, 2008) 24-hour recall + Dietary History 18  19  24 Users of vitamin D supplements 5.5   25.1  
     48  25  34 Users of vitamin D supplements 5.4   20.0  
     134  35  50 Users of vitamin D supplements 5.3   15.0  
     135   51   64 Users of vitamin D supplements 7.3     22.0   
       136   65   80 Users of vitamin D supplements 7.7     22.0   
Supplements Men Austria (Elmadfa et al., 
2009b) 
Quantitative consumption frequency 
questionnaire 
15  18  65 Assessment of the consumption of 
supplements among 282 adults in 
all Austria (77 supplement users) 
 2.0 5.0   
  Germany (MRI, 2008) 24-hour recall + Dietary History 17  19  24 Users of vitamin D supplements 4.2   10.0  
     34  25  34 Users of vitamin D supplements 2.9   5.0  
     90  35  50 Users of vitamin D supplements 4.1   10.0  
     60   51   64 Users of vitamin D supplements 8.5     15.0   
          62   65   80 Users of vitamin D supplements 5.9     15.0   
Foods and 
supplements 
Women Denmark (Tetens et al., 
2011) 
7-day record and interview (data collected in 
2000-2004) 
825  18  49 Supplements users 7.6   15.0  
     599   50   75 Supplements users 8.3     17.0   
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Nutrient 
source Sex Country Reference Dietary assessment method n 
 
Age 
min  
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded Mean Median P75 P95 P97.5 
Foods and 
supplements 
Women Finland (Paturi et al., 
2008) 
48-hour recall and two 3-day records for the 
usual intakes over the past year (assessment 
of underreporters) 
641  25  74 Usual intakes. Underreporters 
excluded 
8.3   16.2  
  Ireland (IUNA, 2011) 4-day record 255  18  35  3.1   8.3 11.8 
     232  36  50  3.5   9.3 13.7 
     153   51   64   6.0     21.3 22.6 
  Norway (Johansson et al., 
1998) 
Food frequency questionnaire 406  16  79 First quartile of n-3 long-chain 
polyunsaturated fatty acid intakes 
5.3     
     406  16  79 Fourth quartile of n-3 long-chain 
polyunsaturated fatty acid intakes 
18.5     
  The 
Netherlands 
(van Rossum et 
al., 2011) 
Two non-consecutive 24-hour dietary recalls 347  19  30   2.9  6.3  
     351  31  50   3.3  7.9  
     353   51   69     3.8   8.7   
Foods and 
supplements 
Men Denmark (Tetens et al., 
2011) 
7-day record and interview 587   18   49 Supplements users 7.8     16.0   
     491   50   75 Supplements users 8.4     16.0   
  Finland (Paturi et al., 
2008) 
48-hour recall and two 3-day records for the 
usual intakes over the past year (assessment 
of underreporters) 
637  25  74 Usual intakes. Underreporters 
excluded 
9.5   18.6  
  Ireland (IUNA, 2011) 4-day record 276  18  35  3.9   10.4 13.6 
     205  36  50  4.7   12.1 16.9 
     153   51   64   5.7     17.1 24.0 
  Norway (Johansson et al., 
1998) 
Food frequency questionnaire 379  16  79 First quartile of n-3 long-chain 
polyunsaturated fatty acid intakes 
5.1     
     378  16  79 Fourth quartile of n-3 long-chain 
polyunsaturated fatty acid intakes 
23.5     
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Nutrient 
source Sex Country Reference Dietary assessment method n 
 
Age 
min  
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded Mean Median P75 P95 P97.5 
Foods and 
supplements 
Men The 
Netherlands 
(van Rossum et 
al., 2011) 
Two non-consecutive 24-hour dietary recalls 356  19  30   3.7  6.7  
     348  31  50   4.2  8.0  
          351   51   69     4.4   8.5   
Foods and 
supplements 
Men and 
women 
Ireland (IUNA, 2011) 4-day record 226   65 > 65   6.9     24.2 29.3 
  United 
Kingdom 
(Bates et al., 
2011) 
4-day record 807  19  64  3.7    12.0 
          224   65 > 65   4.7       14.9 
NB: white lines indicate data for the age-range approximately 19-50 years; grey lines indicate data for the age-range approximately 51 years and over.  
n.a.: not available. 
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B.  INTAKE OF VITAMIN D AMONG CHILDREN IN EUROPEAN COUNTRIES 
Nutrient 
source Sex Country Reference Dietary assessment method n 
 Age 
min 
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded Mean Median P75 P90 P95 P97.5 
Foods and 
supplements 
Girls Finland (Kyttälä et al., 2008; 
2010) 
3-day record 198  1  1 Non-breast-fed infants, 
genetically at-risk of type 1 
diabetes 
12.2  15.0    
Foods and 
supplements 
Boys Finland (Kyttälä et al., 2008; 
2010) 
3-day record 257  1   1 Non-breast-fed infants, 
genetically at-risk of type 1 
diabetes 
12.2   15.1       
Foods and 
supplements 
Boys 
and girls 
The 
Netherlands 
(de Boer et al., 2006) 2-day record (independent days)  55  0.75  0.75 Supplement users 12.5   19.3   
     145  1  1 Supplement users 8.9   14.8   
Foods Girls Denmark (Andersen et al., 
1996) 
7-day record 149  1   3   1.8       3.2   
    The 
Netherlands 
(Ocke et al., 2008) 2-day record (independent days) 313  2   3   1.8       3.3   
Foods Boys Denmark (Andersen et al., 
1996) 
7-day record 129  1   3   1.7       2.4   
    The 
Netherlands 
(Ocke et al., 2008) 2-day record (independent days) 327  2   3   1.8       3.0   
Foods Boys 
and girls 
Greece (Manios et al., 2008) 3-day record (weighed food records 
and 24 h recall or food diaries) 
2,317  1   5 Non-under-reporters. Possible 
inclusion of supplements not 
mentioned 
5.6     11.9     
    Italy (Sette et al., 2010) Consecutive 3-day food records 
 
52  0 < 3 Including fortified food 1.8       5.4   
    United 
Kingdom 
(Bates et al., 2011) 4-day food diary 219  1.5   3   1.9         10.6 
Foods and 
supplements 
Girls Finland (Kyttälä et al., 2008; 
2010) 
3-day record 118  2   2 Genetically at-risk children of 
type 1 diabetes 
9.0   12.6       
          235  3   3   6.9   10.0       
    The 
Netherlands 
(Ocke et al., 2008) 2-day record (independent days) 313  2   3   4.7       10.0   
Foods and 
supplements 
Boys Finland (Kyttälä et al., 2008; 
2010) 
3-day record 112  2   2 Genetically at-risk children of 
type 1 diabetes 
8.7   11.7       
          236  3   3   7.1   9.5       
    The 
Netherlands 
(Ocke et al., 2008) 2-day record (independent days) 327  2   3   4.4       8.7   
Foods and 
supplements 
Boys 
and girls 
The 
Netherlands 
(de Boer et al., 2006) 2-day record (independent days)  251  1.5   1.5 Supplement users 6.7     8.1     
    United 
Kingdom 
(Bates et al., 2011) 4-day food diary 219  1.5   3   2.3         11.8 
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Nutrient 
source Sex Country Reference Dietary assessment method n 
 Age 
min 
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded Mean Median P75 P90 P95 P97.5 
Foods Girls Ireland (IUNA (Irish 
Universities Nutrition 
Alliance), a) 
7-day record 301  5  12  1.6    4.4 5.2 
  The 
Netherlands 
(van Rossum et al., 
2011) 
Two non-consecutive 24-hour 
dietary recalls 
151  7  8   2.3   4.4  
     352  9  13   2.3   4.5  
Foods Boys Ireland (IUNA (Irish 
Universities Nutrition 
Alliance), a) 
7-day record 293  5   12   1.4       3.7 4.4 
  The 
Netherlands 
(van Rossum et al., 
2011) 
Two non-consecutive 24-hour 
dietary recalls 
153  7  8   2.3   4.3  
          351  9   13     2.7     5.0   
Foods Boys 
and girls 
Denmark (Pedersen et al., 
2010) 
7-day record 903  4  14  2.3    5.9  
  Italy (Sette et al., 2010) Consecutive 3-day food records 52  3 < 10 Including fortified food 2.0    5.1  
  Germany (Flynn et al., 2009) 3-day record 1,234  6  11  1.8    4.0  
  Poland (Flynn et al., 2009) 24-hour recall 455  4  10  2.3    5.9  
  Spain (Flynn et al., 2009) 24-hour recall and food frequency 
questionnaire, a second 24-hour 
recall in 25-30 % of the sample 
723  4  10  1.4    2.9  
  The 
Netherlands 
(Flynn et al., 2009) 2-day record (independent days) 639  4  6 Including fortified foods 1.9    3.1  
  United 
Kingdom 
(Bates et al., 2011) 4-day food diary 423  4  10  1.9     4.1 
Foods and 
supplements 
Girls Finland (Kyttälä et al., 2008; 
2010) 
3-day record 247  4   4 Genetically at-risk children of 
type 1 diabetes 
6.1   8.3       
     349  6  6  5.5  6.6    
  The 
Netherlands 
(van Rossum et al., 
2011) 
Two non-consecutive 24-hour 
dietary recalls 
151  7  8   2.5   5.8  
          352  9   13     2.5     5.5   
Foods and 
supplements 
Boys Finland (Kyttälä et al., 2008; 
2010) 
3-day record 307  4   4 Genetically at-risk children of 
type 1 diabetes 
5.9   7.7       
     364  6  6  6.3  7.7    
Tolerable Upper Intake Level of vitamin D 
 
EFSA Journal 2012;10(7):2813 35 
Nutrient 
source Sex Country Reference Dietary assessment method n 
 Age 
min 
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded Mean Median P75 P90 P95 P97.5 
Foods and 
supplements 
Boys The 
Netherlands 
(van Rossum et al., 
2011) 
Two non-consecutive 24-hour 
dietary recalls 
153  7  8   2.8   6.3  
          351  9   13     3.0     6.3   
Foods and 
supplements 
Boys 
and girls 
Germany (Flynn et al., 2009) 3-day record 1234  6  11  1.8    5.0  
  Ireland (IUNA (Irish 
Universities Nutrition 
Alliance), a) 
7-day record 594  5  12  2.3    6.4  
  Spain (Flynn et al., 2009) 24-hour recall and food frequency 
questionnaire, a second 24-hour 
recall in 25-30 % of the sample 
723  4  10 Including fortified food 1.8    3.0  
  Sweden (Enghardt-Barbieri et 
al., 2006) 
4-day record 590  4  4  6.6    15.4  
     889  8  9  5.0    10.4  
     1,016  11  12  4.6    10.1  
  The 
Netherlands 
(Flynn et al., 2009) 2-day record (independent days) 639  4  6  2.6    5.3  
     639  4  6 Including fortified foods 2.7    5.5  
    United 
Kingdom 
(Bates et al., 2011) 4-day food diary 423  4   10   2.6         7.3 
Foods Girls Belgium (Sioen et al., 2007b) 7-day record 212  13   18 Data collected in the region of 
Ghent in Flanders. 
2.5       4.9   
    Denmark (Pedersen et al., 
2010) 
7-day record 134  14   17   1.9       5.0   
    Ireland (IUNA (Irish 
Universities Nutrition 
Alliance), b) 
7-day record 217  13   17   1.8       4.5 6.0 
    Italy (Sette et al., 2010) Consecutive 3-day food records 139  10 < 18 Including fortified food 2.4       6.7   
    The 
Netherlands 
(van Rossum et al., 
2011) 
Two non-consecutive 24-hour 
dietary recalls 
354  14   18     2.4     4.6   
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Nutrient 
source Sex Country Reference Dietary assessment method n 
 Age 
min 
(years) 
 
Age 
max 
(years) 
Population / Fortified foods 
included or excluded Mean Median P75 P90 P95 P97.5 
Foods Boys Belgium (Sioen et al., 2007b) 7-day record 129  13   18 Data collected in the region of 
Ghent in Flanders. 
4.05       7.6   
    Denmark (Pedersen et al., 
2010) 
7-day record 101  14   17   3.0       6.8   
    Ireland (IUNA (Irish 
Universities Nutrition 
Alliance), b) 
7-day record 224  13   17   2.4       6.0 7.5 
    Italy (Sette et al., 2010) Consecutive 3-day food records 108  10 < 18 Including fortified food 2.6       7.7   
    The 
Netherlands 
(van Rossum et al., 
2011) 
Two non-consecutive 24-hour 
dietary recalls 
352  14   18     3.1     5.5   
Foods Boys 
and girls 
Germany (Flynn et al., 2009) 3-day record 1,272  12   17  2.4       5.5   
  Spain (Flynn et al., 2009) 24-hour recall and food frequency 
questionnaire, a second 24-hour 
recall in 25-30 % of the sample 
1,137  11   17  1.6       3.0   
    United 
Kingdom 
(Bates et al., 2011) 4-day food diary 453  11   18   2.1         5.5 
Foods and 
supplements 
Girls The 
Netherlands 
(van Rossum et al., 
2011) 
Two non-consecutive 24-hour 
dietary recalls 
354  14   18     2.6     5.4   
Foods and 
supplements 
Boys The 
Netherlands 
(van Rossum et al., 
2011) 
Two non-consecutive 24-hour 
dietary recalls 
352  14   18     3.3     6.1   
Foods and 
supplements 
Boys 
and girls 
Germany (Flynn et al., 2009) 3-day record 1,272  12   17   2.5       6.3   
    Ireland (IUNA (Irish 
Universities Nutrition 
Alliance), b) 
7-day record 441  13   17   2.7       7.6   
  Poland (Flynn et al., 2009) 24-hour recall 581  11   17   4.0       9.7   
    Spain (Flynn et al., 2009) 24-hour recall and food frequency 
questionnaire, a second 24-hour 
recall in 25-30 % of the sample 
1,137  11   17 Including fortified food 1.9       3.2   
    United 
Kingdom 
(Bates et al., 2011) 4-day food diary 453  11   18   2.3         6.5 
NB: First white section: infants. First grey section: ~1-3 years. Second white section: older children. Second grey section: ~adolescents. 
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C.   VITAMIN D INTAKE AND HYPERCALCAEMIA IN ADULTS 
Author Study 
Design 
Duration Number at 
entry and 
type of 
subjects 
Age range Sex Completers Vitamin D 
supplement 
Ca 
supple-
ment 
Effect Intervention group  
with highest dose 
Effect Control group Hyper-
calcaemia 
Remarks 
  
(months)   (years) (m/f) (n) 
Equivalent daily 
dose (µg/day) (mg/day) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D  
 
 
(nmol/L) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D 
 
 
(nmol/L) (Yes / No) 
 
Zittermann et 
al., 2009 
 
Bad 
Oeynhausen, 
Germany 
(latitude 52°N) 
Rando-
mised, 
double-
blind, 
placebo- 
controlled 
12 
(starting 
December) 
200 
healthy 
overweight 
adults 
18-70 62 m 165 83.3 µg vitamin 
D3/day  
No  t0: 2.36±0.08 t12: 
2.38±0.10 
 
Δ: 0.02±0.09 
t0: 30.0±17.5  
t12: 85.5±57.5  
 
Δ: 55.5±55.8 
t0: 2.38±0.10 
t12: 2.40±0.25 
 
Δ: 0.02±0.24 
t0: 30.3±20.1 
t12: 42.0±35.0 
 
Δ: 11.8±36.3 
No  
Narang et al., 
1984 
 
Ajmer, India 
(latitude 26°N) 
Inter-
vention 
trial 
3 (season not 
reported) 
30 
healthy 
adults 
21-60 both not reported 10, 20, 30, 
60, or 95 µg 
vitamin D/day   
 
 
No 60 µg D/day: 
t0: 2.43±0.13 
t3: 2.62±0.22 
 
95 µg D/day: 
t0: 2.46±0.09 
t3: 2.83±0.21 
Not reported 10 µg D/day: 
t0: 2.4±0.06 
t3: 2.5±0.13 
Not reported Not reported  
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Author Study 
Design 
Duration Number at 
entry and 
type of 
subjects 
Age range Sex Completers Vitamin D 
supplement 
Ca 
supple-
ment 
Effect Intervention group  
with highest dose 
Effect Control group Hyper-
calcaemia 
Remarks 
  
(months)   (years) (m/f) (n) 
Equivalent daily 
dose (µg/day) (mg/day) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D  
 
 
(nmol/L) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D 
 
 
(nmol/L) (Yes / No) 
 
Aloia et al., 
2008 
 
Long Island in 
NY, USA 
(latitude 40°N) 
Rando-
mised, 
double-
blind, 
placebo-
controlled 
6 
(3 successive 
winters 
November - 
March) 
138 white 
(76) and 
African-
American 
(62) 
18–65 both 111 Dose of vitamin 
D3 based on 
initial 
25(OH)D 
concentration 
and adjusted at 
week 9 and week 
18: 
 
dose range up to 
week 9:  
50-100 µg/day,  
 
subsequent dose 
range: 20-
170 µg/day, 
  
median dose: 
95 µg vitamin 
D3/day  
No t6: < 2.65 To obtain and 
maintain serum 
25(OH)D  
>80 nmol/L and 
< 140 nmol/L 
throughout the 
study 
t6:< 2.65 Δ: 19.5±16.0 No  
 
4 patients with 
hypercalciuria 
on several 
occasions 
equally often 
in vitamin D 
and placebo 
group 
Vieth et al., 
2001 
 
Toronto, 
Canada 
(latitude 43°N) 
Rando-
mised 
5 
(starting 
between 
January and 
February) 
73 
healthy 
adults 
18-56 both 61 
completed 
≥1 month 
25 or 100 µg/day 
D3 
No mean <2.45,  
all subjects 
remained within 
reference range 
(2.2-2.6) 
100 µg/day: 
t0: 37.9±13.4 
 
plateau after 3 
months at mean 
(range) of 96 
(69-125) 
n/a n/a No 
 
On a group 
basis, no 
change from 
baseline in 
urinary molar 
Ca:creatinine 
ratios in 
randomly 
collected urine 
samples. In 1 
subject on 
100 µg/day D3, 
hypercalciuria 
occurred in 2 
of 6 measure-
ments, but 
time points not 
specified. 
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Author Study 
Design 
Duration Number at 
entry and 
type of 
subjects 
Age range Sex Completers Vitamin D 
supplement 
Ca 
supple-
ment 
Effect Intervention group  
with highest dose 
Effect Control group Hyper-
calcaemia 
Remarks 
  
(months)   (years) (m/f) (n) 
Equivalent daily 
dose (µg/day) (mg/day) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D  
 
 
(nmol/L) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D 
 
 
(nmol/L) (Yes / No) 
 
Relative 
number of 
occurrences of 
hypercalciuria 
across the 
entire follow-
up period was 
not different 
between 
groups. 
Tjellesen et al., 
1986 
 
Copenhagen, 
Denmark 
(latitude 55°N) 
Rando-
mised, 
double-
blind 
uncon-
trolled 
8 weeks 
(September-
November) 
19 
healthy 
premeno-
pausal 
women 
22-49 f 19 97 µg/day D2 or 
110 µg/day D3 
500 97 µg/day D2: 
t0: 2.46±0.03 
t8: 2.46±0.01 
 
110 µg/day D3: 
t0: 2.46±0.02 
t8: 2.51±0.02, 
p<0.02, 
mean±SEM 
97 µg/day D2: 
t0: 75 (55-96) 
t8: 89 (49-121) 
 
110 µg/day D3: 
t0: 77 (46-100) 
t8: 113 (77-138), 
median (range) 
n/a n/a Not reported  
Gallagher et 
al., 2012 
 
Omaha, 
Nebraska 
(latitude 41°N) 
Rando-
mised, 
placebo-
controlled 
12 
(screening in 2 
successive 
years in April 
or January to 
May, enroll-
ment on 
average 5 
weeks after 
screening) 
163 
healthy 
postmeno-
pausal white 
women with 
25(OH)D 
<50 nmol/L 
 
57-90 f 147 0, 12.6, 22.8, 
38.3, 64.8, 
73.7, 105.2, or  
123.4 µg/day D3 
(analysed doses) 
Yes, to 
obtain a 
total Ca 
intake of 
1,200-
1,400 
105.2 µg/day D3: 
t0: 2.35±0.1 
t12: not reported 
 
123.4 µg/day D3: 
t0: 2.37±0.075 
t12: not reported 
 
105.2 µg/day D3: 
t0: 37.2±9.2 
t12: 112.9 
 
123.4 µg/day D3: 
t0: 38.6±9.1 
t12: 115.0 
 
(Values at 12 
months 
calculated on the 
basis of the 
estimated dose-
response curve) 
t0: 2.37±0.1 
t12: not reported 
 
t0:37.7±9.1 
t12:54.5 
 
(Values at 12 
months 
calculated on the 
basis of the 
estimated dose-
response curve) 
5 subjects ≥2.7 
mmol/L, 1 in 
highest dose 
group, others on 
12.6, 22.8, 
64.8 µg D3/day. 
16 subjects ≥2.5 
mmol/L, 2 in 
highest dose 
group, rest in all 
other groups 
including 
placebo; all 
normal at repeat 
testing within 2 
weeks 
19 subjects 
with 
hypercalciuria 
(>400 mg 
Ca/day), 2 in 
highest dose 
group, rest in 
all other 
groups 
including 
placebo, 
normal at 
repeat testing 
in all but 3 
subjects in 
which Ca or 
Ca+D3 was 
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Author Study 
Design 
Duration Number at 
entry and 
type of 
subjects 
Age range Sex Completers Vitamin D 
supplement 
Ca 
supple-
ment 
Effect Intervention group  
with highest dose 
Effect Control group Hyper-
calcaemia 
Remarks 
  
(months)   (years) (m/f) (n) 
Equivalent daily 
dose (µg/day) (mg/day) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D  
 
 
(nmol/L) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D 
 
 
(nmol/L) (Yes / No) 
 
then 
withdrawn 
Mocanu et al., 
2009 
 
Iasi, Romania 
(latitude 47°N) 
Uncon-
trolled 
12 
(November-
December) 
45 
nursing 
home 
residents 
58-89 both 40 125 µg/day D3 
via fortified 
bread 
320 t0: 2.29±0.15 
(2.1-2.65) 
 
t12: 2.28±0.15 
(1.9-2.55) 
t0: 28.8±9.9 
t12: 126.4±37.3 
(slightly different 
values reported 
in abstract) 
Δ: 98.0 (median) 
n/a n/a No 3 subjects with 
molar 
Ca:creatinine 
ratio >1 on one 
occasion at 6 
or 9 months in 
the study 
Jorde et al., 
2010  
(also described 
in Sneve et al., 
2008) 
 
Tromso, 
Norway 
(latitude 69°N) 
Rando-
mised, 
double-
blind, 
placebo- 
controlled 
12 
(starting 
November) 
438 over-
weight or 
obese adults 
21-70 both 330 0, 71, or 143 
µg/day D3 
500 71 µg/day D3: 
t0: 2.32±0.11 
Δ: -0.01±0.11 
 
143 µg/day D3: 
t0: 2.30±0.11 
Δ: 0.00±0.12 
71 µg/day D3: 
t0: 56.7±21.2 
Δ: +42.8±22.5 
 
143 µg/day D3: 
t0: 58.7±21.2 
Δ: +79.3±31.2 
t0: 2.31±0.10 
Δ: -0.01±0.11 
t0: 58.8±21.0 
Δ: -1.6±16.8 
3 excluded 
because of 2 
serum 
measurements 
>2.6 mmol/L (1 
in Ca-only group, 
2 in Ca + low 
D3), 4 subjects 
with transient 
increase in serum 
Ca (1 in Ca-only, 
3 in Ca + high 
D3) who 
remained in 
study 
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Author Study 
Design 
Duration Number at 
entry and 
type of 
subjects 
Age range Sex Completers Vitamin D 
supplement 
Ca 
supple-
ment 
Effect Intervention group  
with highest dose 
Effect Control group Hyper-
calcaemia 
Remarks 
  
(months)   (years) (m/f) (n) 
Equivalent daily 
dose (µg/day) (mg/day) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D  
 
 
(nmol/L) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D 
 
 
(nmol/L) (Yes / No) 
 
Grimnes et al., 
2012 
 
Tromso, 
Norway 
(latitude 69°N) 
Rando-
mised, 
double-
blind 
12 
(subjects were 
asked to report 
on mean time 
spent outdoors 
between 10 
AM and 3 PM 
in March–
April and 
September 
and between 8 
AM and 8 PM 
in June–
August) 
297 
postmeno-
pausal 
women with 
reduced 
bone mineral 
density 
50-80 f 275 20 or 163 µg/day 
D3 
1,000 20 µg/day D3: 
t0: 2.36±0.07 
Δ: 0.00±0.10 
 
163 µg/day D3: 
t0: 2.36±0.09 
Δ: 0.02±0.09 
20 µg/day D3: 
t0: 71.2±22.3 
Δ: +18.0±18.9 
 
163 µg/day D3: 
t0: 70.7±23.0 
Δ: +114.7±34.6 
n/a n/a Modest 
hypercalcaemia 
(defined as serum 
calcium of 2.6-
2.8 mmol/L) was 
reported for 9 
women in the 
high-dose group 
and 4 women in 
the low-dose 
group, at serum 
25(OH)D 
concentrations 
across a range of 
64-256 nmol/L, 
all resolved at 
retesting 
 
Berlin et al., 
1986 
(also described 
in Berlin T and 
Björkhem I, 
1987) 
 
Stockholm, 
Sweden 
(latitude 59°N) 
Control-
led 
7 weeks 
(March-April) 
24 
healthy 
Swedish 
22-47 m 24 193 µg/day D3 No t0: 2.47±0.03 
t7: 2.49±0.03 
 
(mean±SEM) 
t0: 38±4 
t7: 123±5 
 
(mean±SEM) 
t0: 2.50±0.02 
t7: 2.44±0.04 
 
(mean±SEM) 
t0: 37±2 
t7: 48±3 
 
(mean±SEM) 
Not reported No side effects 
were recorded. 
Heaney et al., 
2003 
 
Omaha, USA 
(latitude 41°N) 
Rando-
mised, 
controlled 
20 weeks: 
(winter 
months of 2 
successive 
years: late 
October-late 
February/ 
early March) 
67 
healthy 
adults 
38.7±11.2 m not reported 0, 20.9, 137.5, or 
275 µg/day D3 
(analysed doses) 
No t0: 2.4, 
no change 
from baseline at 
any time point 
(1, 3, 6, 10, 20 
weeks) for 
subjects in two 
highest dose 
groups 
t0: 70.3±19.9 
for all subjects 
 
137.5 µg/day: 
Δ: +91.9±37.6 
 
275 µg/day: 
Δ: +159.4±62.4 
Not reported 
 
 
Δ: -11.4±17.7 No  
(all 31 subjects in 
two highest dose 
groups <2.6 
mmol/L) 
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Author Study 
Design 
Duration Number at 
entry and 
type of 
subjects 
Age range Sex Completers Vitamin D 
supplement 
Ca 
supple-
ment 
Effect Intervention group  
with highest dose 
Effect Control group Hyper-
calcaemia 
Remarks 
  
(months)   (years) (m/f) (n) 
Equivalent daily 
dose (µg/day) (mg/day) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D  
 
 
(nmol/L) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D 
 
 
(nmol/L) (Yes / No) 
 
Rickers et al., 
1982 
 
Glostrup, 
Denmark 
(latitude 54°N) 
Rando-
mised, 
controlled 
24 weeks 31 
patients 
under 
treatment 
with 
prednisone 
for various 
diseases 
27-81 both 31 321 µg/day D2 
(in combination 
with prednisone 
and 50 mg/day 
sodium fluoride) 
4,500 
calcium 
phosphate 
t0: 2.48±0.05 
t24:2.46±0.03   
 
(mean±SEM) 
25(OH)D2 
t0: 4.2±1.2 
t24: 145.3±19.0 
 
25(OH)D3 
t0: 38.4±4.2 
t24: 10.2±1.2 
 
(mean±SEM) 
t0: 2.50±0.04 
t24:2.44±0.05 
 
(mean±SEM) 
25(OH)D2 
t0: 8.7±2.2 
t24: 7.2±3.5 
 
25(OH)D3 
t0: 42.7±5.5 
t24: 34.4 ±5.5 
 
(mean±SEM) 
Not reported  
Hasling et al., 
1987 
 
Aarhus, 
Denmark 
(latitude 56°N) 
Uncon-
trolled 
5 years 
(mean 
observation 
time 2.8 years) 
163 
consecutive 
patients with 
spinal crush 
fracture 
osteopo-rosis 
16-84 both 43 450 µg/day D2 
(in combination 
with 60 mg/day 
sodium fluoride) 
1,800 t0: 2.50±0.1 
t5y:2.45±0.06, 
p<0.001, 
no change at 6-
12 months 
(n=152 patients) 
levels increased 
during treatment 
(reported in 
Charles et al., 
1985) 
n/a n/a No 
hypercalcaemic 
episodes were 
observed 
Urinary Ca 
excretion did 
not change 
during 
treatment. 
Barger-Lux et 
al., 1998 
 
Omaha, USA 
(latitude 41°N) 
Open-label 8 weeks 
(Jan-April) 
38 
healthy 
20-37 male 38 35, 234, or 1,269 
µg/day D3  
 
(analysed doses) 
No Not reported t0 in all 116 
subjects in study: 
67±25 
  
35 µg D3/day: 
Δ: +28.6±5.3  
 
234 µg D3/day: 
Δ: +146.1±12.0  
 
1,269 µg D3/day: 
Δ: +643.0±42.7 
(mean±SEM) 
n/a n/a “no 
hypercalcaemia 
was detected in 
post-treatment 
testing of our 
vitamin D3- 
treated subjects” 
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Author Study 
Design 
Duration Number at 
entry and 
type of 
subjects 
Age range Sex Completers Vitamin D 
supplement 
Ca 
supple-
ment 
Effect Intervention group  
with highest dose 
Effect Control group Hyper-
calcaemia 
Remarks 
  
(months)   (years) (m/f) (n) 
Equivalent daily 
dose (µg/day) (mg/day) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D  
 
 
(nmol/L) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D 
 
 
(nmol/L) (Yes / No) 
 
Schwartzman 
and Franck, 
1987 
 
New York, 
USA 
(latitude 42°N) 
Case 
reports 
6 weeks – 
5 years 
4 patients 
with 
osteoporo-sis 
(3) or 
osteomala-
cia (1);  
2 of 4 with 
corticoid 
therapy;  
1 with renal 
insufficien-
cy 
42-77 f n/a 1,250 µg/? 
 
 
179 µg/day D2 
 
 
1,250 µg/day 
 
 
357 µg/day D2 
 
Yes, dose 
unknown 
 
Yes, dose 
unknown 
 
400 
 
 
400 
3.35 
 
 
2.88 
 
 
3.75 
 
 
Not reported 
354 
 
 
Not reported 
 
 
339 
 
 
634 
 
 
n/a n/a Yes  
Selby et al., 
1995 
 
 
Manchester, 
UK  
(latitude 53°N) 
Case 
reports 
10 years 
 
 
2 years 
 
 
10 years 
 
 
13 years 
 
 
unknown 
 
 
2 years 
6 
patients with 
hypopara-
thyroidism, 
hypophos-
phataemic 
rickets, 
coelic 
disease, 
paraesthe-
siae or 
unknown 
reason for 
vitamin D 
therapy 
51 
 
 
14 
 
 
47 
 
 
52 
 
 
36 
 
 
57 
both n/a 2,500 µg/day 
 
 
5,000 µg/day 
 
 
2,500 µg/day 
 
 
2,500 µg/day 
 
 
unknown 
 
 
5,000 µg/day 
Not 
reported 
3.19 
 
 
3.00 
 
 
3.24 
 
 
3.31 
 
 
3.07 
 
 
3.77 
 866 
 
 
 802 
 
 
1005 
 
 
 533 
 
 
 643 
 
 
1203 
n/a n/a Yes  
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Author Study 
Design 
Duration Number at 
entry and 
type of 
subjects 
Age range Sex Completers Vitamin D 
supplement 
Ca 
supple-
ment 
Effect Intervention group  
with highest dose 
Effect Control group Hyper-
calcaemia 
Remarks 
  
(months)   (years) (m/f) (n) 
Equivalent daily 
dose (µg/day) (mg/day) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D  
 
 
(nmol/L) 
serum Ca 
 
 
(mmol/L) 
serum 25(OH)D 
 
 
(nmol/L) (Yes / No) 
 
Davies and 
Adams, 1978 
 
Manchester, 
UK  
(latitude 53°N) 
Case 
reports 
Several years 
 
 
7 years 
 
10 years 
 
4 months 
 
3 years 
 
2 years 
 
9 months 
 
10 years 
8 
patients with 
hypopara-
thyroidism, 
Paget's 
disease, 
arthritis, vit. 
D-resistant 
rickets, 
osteopo-
rosis, or 
symptoms 
suggesting 
carpal-tunnel 
syndrome 
59 
 
 
71 
 
51 
 
55 
 
60 
 
15 
 
30 
 
44 
both n/a 1,250-2,500 µg 
D2/day 
 
3,750 µg D2/day  
 
2,500 µg/day 
 
3,750 µg/day 
 
1,250 µg/day 
  
5,000 µg/day 
 
1,250 µg/day  
 
2,500 µg/day  
Yes, dose 
not 
specified; 
not 
reported 
for all 
other cases 
3.1 
 
 
4.5 
 
3.75 
 
3.9 
 
4.3 
 
3.1 
 
4.0 
 
3.1 
Not reported 
 
 
1,123 
 
998 
 
Not reported 
 
Not reported 
 
Not reported 
 
Not reported 
 
Not reported 
n/a n/a Yes  
Rizzoli et al., 
1994 
 
Geneva, 
Switzerland 
(latitude 69°N) 
Case 
reports 
96 weeks 
 
 3 weeks 
 
74 weeks 
 
12 weeks 
 
 4 weeks 
 
 4 weeks 
6 
patients with 
osteoporo-
sis, or 
hypopara-
thyroidism 
72 
 
56 
 
50 
 
66 
 
84 
 
79 
both n/a 2,143 µg/day D3 
 
7,500 µg/day D3 
 
7,500 µg/day D3 
 
1,071 µg/day D3 
 
7,500 µg/day D3 
 
7,500 µg/day D3 
Not 
reported 
3.55 
 
2.83 
 
3.30 
 
2.53 
 
4.59 
 
3.29 
221 
 
801 
 
1,692 
 
374 
 
650 
 
621 
n/a n/a Yes, in all but 
one patient who 
was considered 
vitamin D 
intoxicated on 
the basis of signs 
of enhanced bone 
resorption, 
history of 
excessive vit. D 
intake and 
increased 
25(OH)D 
concentration 
 
n/a: not applicable; m: males; f: females 
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GLOSSARY AND ABBREVIATIONS 
25(OH)D 25-Hydroxy-vitamin D (sum of 25-Hydroxy-vitamin D2 and 25-Hydroxy-vitamin D3) 
1,25(OH)2D Active metabolite/vitamin D hormone 
BMI  Body mass index 
CI  Confidence interval 
CYP  Cytochrome P 
IoM  Institute of Medicine 
LOAEL Lowest observed adverse effect level 
NHANES United States National Health and Nutrition Examination Survey 
NOAEL No observed adverse effect level 
OR  Odds ratio 
RCT  Randomised controlled trial 
SCF  Scientific Committee on Food 
SEM  Standard error of the mean 
SGA  Small-for-gestational age 
UL  Tolerable Upper Intake Level 
UV  Ultraviolet 
Vitamin D2 Ergocalciferol (also termed viosterol) 
Vitamin D3 Cholecalciferol 
